In the era of precision medicine, it has been increasingly recognized that individuals with a
certain disease are complex and different from each other. Due to the underestimation of the …

Oncogenic driver mutations have implications that extend beyond cancer cells themselves.
Aberrant tumour cell signalling has various effects on the tumour microenvironment and anti …

We have shown that KRAS–TP53 genomic coalteration is associated with immune-excluded
microenvironments, chemoresistance, and poor survival in pancreatic ductal …

KRAS-TP53 co-mutation is strongly associated with poor prognosis and high malignancy in
gastrointestinal cancers. Therefore, a novel approach to oncotherapy may lie in combination …

While RNA therapeutics hold great promise for combating pancreatic ductal
adenocarcinoma (PDAC), the limited therapy outcome due to the insufficient delivery …

RAS pathway mutations, which are present in 30% of patients with chronic myelomonocytic
leukemia (CMML) at diagnosis, confer a high risk of resistance to and progression after …

Pancreatic ductal adenocarcinoma (PDAC) is a digestive system malignancy characterized
by challenging early detection, limited treatment alternatives, and generally poor prognosis …

The KRAS mutation stands out as one of the most influential oncogenic mutations, which
directly regulates the hallmark features of cancer and interacts with other cancer-causing …

Background The aim of this study was to construct a predictive signature integrating tumour-
mutation-and copy-number-variation-associated features using machine learning to …

Objective Pancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options,
particularly with immune checkpoint inhibitors. Highly chemoresistant 'stem-like'cells, known …